Skip to main content

Table 1 Comparison of glucagon like peptide-1 receptor agonist (GLP1RA) cardiovascular outcome trials (CVOTs)

From: Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis

Study Design Medications Sample size
N
Male sex
N (%)
Age, years
Mean (SD)
Median follow-up
years
Duration of diabetes, years
Mean (SD)
HbA1c, % Mean (SD) Existence of CVD
N (%)
Statin use
N (%)
SGLT-2i use
N (%)
ELIXA Randomized, double-blind, placebo-controlled trial Lixisenatide once daily vs placebo 6068 4207 (69) 59.9 (9.7)b 2.1 9.2 (8.2)b 7.7 (1.3)b 6068 (100) 5627 (92.7) NA
LEADER Randomized, double-blind, placebo-controlled trial Liraglutide once daily vs placebo 9340 6003 (64) 64.2 (7.2)b 3.8 12.8 (8.0)b 8.7 (1.6)b 7598 (81) 6741 (72.2) NA
SUSTAIN-6 Randomized, double-blind, placebo-controlled trial Semaglutide once weekly vs placebo 3297 2002 (61) 64.6 (7.4) 2.1 13.9 (8.1) 8.7 (1.5) 2735 (83)c 2399 (72.8) 5 (0.2)
EXSCEL Randomized, double-blind, placebo-controlled trial Exenatide once weekly vs placebo 14,752 9148 (62) 62.7 (3.6)d 3.2 12.3 (3.2)d 8.1 (0.5)d 10,782 (73) 10,836 (73.5) 77 (0.9)
HARMONY Randomized, double-blind, placebo-controlled trial Albiglutide once weekly vs placebo 9463 6569 (69) 64.1 (8.7)b 1.6 14.1 (8.6)b 8.7 (1.5)b 6678 (71) 7955 (84.1) 575 (6.1)
REWIND Randomized, double-blind, placebo-controlled trial Dulaglutide once weekly vs placebo 9901 5312 (53.7) 66.2 (6.5) 5.4 10.5 (7.3)b 7.3 (1.1)b 3114 (31) 6547 (66.1) 3 (0.0)
PIONEER-6 Randomized, double-blind, placebo-controlled trial Semaglutide once dailya vs placebo 3183 2176 (68.4) 66 (7.0) 1.3 14.9 (8.5) 8.2 (1.6) 2695 (85)c 2712 (85.2)e 305 (9.6)
  1. ELIXA the evaluation of lixisenatide in acute coronary syndrome trial; LEADER the liraglutide effect and action in diabetes evaluation of cardiovascular outcome results trial; SUSTAIN-6 the preapproval trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes; EXSCEL the exenatide study of cardiovascular event lowering; HARMONY a long term, randomized, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with type 2 diabetes mellitus; CVD cardiovascular disease; SD standard deviation; HbA1c glycated hemoglobin
  2. aOral semaglutide
  3. bData retrieved from the treatment arm
  4. cPresented in the trial as total of CVD and/or chronic kidney disease
  5. dEstimated based on the median range, and the sample size
  6. ePresented in the trial as lipid lowering agents in general